Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
250 hedge funds and large institutions have $5.11B invested in Medicines Co in 2019 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 108 increasing their positions, 58 reducing their positions, and 32 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 58
75% more funds holding in top 10
Funds holding in top 10: 8 → 14 (+6)
72% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 32
36% more capital invested
Capital invested by funds: $3.76B → $5.11B (+$1.35B)
10% more funds holding
Funds holding: 228 → 250 (+22)
17% less call options, than puts
Call options by funds: $489M | Put options by funds: $586M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$72.7M |
| 2 |
BlackRock
New York
|
+$37.7M |
| 3 |
Renaissance Technologies
New York
|
+$26.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$25M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$62M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$59.1M |
| 3 |
BM
Bridger Management
New York
|
-$36.2M |
| 4 |
AH
Aviva Holdings
New Providence,
Bahamas
|
-$34.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$33.2M |
MDCO Hedge Fund Activity: Q3 2019 in Review
250 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q3 2019, worth a combined $5.11B — up 36% from $3.76B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new MDCO positions and 32 closed out — a net gain of 23 holders — while 108 added to existing stakes and 58 trimmed.
The largest buyer was Westfield Capital Management, adding an estimated $72.7M. The largest seller was Camber Capital Management, exiting entirely with an estimated $62M sold.
- 250 institutional investors held Medicines Co (MDCO) as of Q3 2019, up from 228 in Q2 2019.
- Funds reported $5.11B of Medicines Co stock for Q3 2019, up 36% quarter-over-quarter.
- 55 funds opened new Medicines Co positions in Q3 2019 and 32 closed out, a net change of +23 holders.
- The largest Medicines Co buyer in Q3 2019 was Westfield Capital Management, an estimated $72.7M added.
- The largest Medicines Co seller in Q3 2019 was Camber Capital Management, an estimated $62M sold.
Based on aggregated 13F filings for Q3 2019.